OncoDermatology Clinic, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico.
Ecology of Pathogenic Agents, Division of Research, General Hospital Dr. Manuel Gea González, Mexico.
Indian J Dermatol Venereol Leprol. 2022 Sep-Oct;88(5):608-614. doi: 10.25259/IJDVL_627_19.
Background Melanoma is an aggressive cutaneous cancer. Acral lentiginous melanoma is a melanoma subtype arising on palms, soles, and nail-units. The incidence, prevalence and prognosis differ among populations. The link between expression of major histocompatibility complex Class II alleles and melanoma progression is known. However, available studies report variable results regarding the association of melanoma with specific HLA Class II loci. Aims The aim of the study was to determine HLA Class II allele frequencies in acral lentiginous melanoma patients and healthy Mexican Mestizo individuals. Methods Eighteen patients with acral lentiginous melanoma and 99 healthy controls were recruited. HLA Class II typing was performed based on the sequence-specific oligonucleotide method. Results Three alleles were associated with increased susceptibility to develop acral lentiginous melanoma, namely: HLA-DRB113:01; pC = 0.02, odds ratio = 6.1, IC95% = 1.4-25.5, HLA-DQA101:03; pC = 0.001, odds ratio = 9.3, IC95% = 2.7-31.3 and HLA-DQB102:02; pC = 0.01, odds ratio = 3.7, IC95% = 1.4-10.3. Limitations The small sample size was a major limitation, although it included all acral lentiginous melanoma patients seen at the dermatology department of Dr. Manuel Gea González General Hospital during the study period. Conclusion HLA-DRB113:01, HLA-DQB102:02 and HLA-DQA01:03 alleles are associated with increased susceptibility to develop acral lentiginous melanoma in Mexican Mestizo patients.
黑色素瘤是一种侵袭性皮肤癌。肢端雀斑样黑色素瘤是一种发生于手掌、足底和甲单元的黑色素瘤亚型。发病率、患病率和预后在不同人群中存在差异。主要组织相容性复合体 II 类等位基因的表达与黑色素瘤进展之间的联系是已知的。然而,现有研究报告了黑色素瘤与特定 HLA II 类基因座之间关联的可变结果。
本研究旨在确定肢端雀斑样黑色素瘤患者和健康墨西哥混血个体中 HLA II 类等位基因的频率。
招募了 18 名肢端雀斑样黑色素瘤患者和 99 名健康对照者。基于序列特异性寡核苷酸方法进行 HLA II 类分型。
有三个等位基因与肢端雀斑样黑色素瘤的易感性增加相关,即:HLA-DRB113:01;pC = 0.02,优势比 = 6.1,95%CI = 1.4-25.5,HLA-DQA101:03;pC = 0.001,优势比 = 9.3,95%CI = 2.7-31.3 和 HLA-DQB1*02:02;pC = 0.01,优势比 = 3.7,95%CI = 1.4-10.3。
尽管该研究包括了研究期间在曼努埃尔·赫亚·冈萨雷斯综合医院皮肤科就诊的所有肢端雀斑样黑色素瘤患者,但样本量小是一个主要限制。
在墨西哥混血患者中,HLA-DRB113:01、HLA-DQB102:02 和 HLA-DQA*01:03 等位基因与肢端雀斑样黑色素瘤易感性增加相关。